Belite Bio, Inc (BLTE) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $139.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in... Read more
Sell if holding. Engine safety override at $139.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Oversold RSI 29, near Bollinger lower, volume surge. Score 5.6/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 1d<=7d. Suitability: moderate.
Recent Developments — Belite Bio, Inc
Latest news
- Earnings Scheduled For May 20, 2026 — benzinga May 20, 2026 neutral
- Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate — benzinga May 20, 2026 positive
- Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt Disea — benzinga May 18, 2026 positive
- Belite Bio To Present Topline Data From Phase 3 DRAGON Study Of Stargardt Disease Type 1 Treatment At 27th Fundus Diseas — benzinga May 15, 2026 positive
- HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target — benzinga Apr 22, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $139.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Oversold RSI 29, near Bollinger lower, volume surge. Prior stop was $133.35. Score 5.6/10, moderate confidence.
Take-profit target: $184.00 (+31.7% upside). Prior stop was $133.35. Stop-loss: $133.35.
Quality below floor (1.6 < 4.0).
Belite Bio, Inc trades at a P/E of N/A (forward 182.0). TrendMatrix value score: 5.2/10. Verdict: Sell.
14 analysts cover BLTE with a consensus score of 4.2/5. Average price target: $212.
What does Belite Bio, Inc do?Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development...
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.